Epithalon

What is Epithalon?

Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is designed to mimic the action of epithalamin, a naturally occurring peptide produced by the pineal gland that declines with age.

The central claim is extraordinary: Epithalon activates telomerase, the enzyme that rebuilds telomeres (the protective caps on the ends of your chromosomes). Telomeres shorten with every cell division, and their length is one of the most reliable biomarkers of biological ageing. If you can slow or reverse telomere shortening, you are — in theory — slowing the ageing clock at its most fundamental level.

Khavinson's research spans decades. He has published over 800 papers on peptide bioregulators and conducted human trials showing increased telomere length, improved immune function, and normalised circadian rhythms in elderly patients. The work is genuine and peer-reviewed, though largely published in Russian journals and not widely replicated by Western labs. This is the source of both the excitement and the scepticism.

How Does It Work?

Epithalon activates telomerase (hTERT — human telomerase reverse transcriptase), which adds telomeric repeats (TTAGGG) to chromosome ends. This directly counters replicative senescence — the process by which cells stop dividing once telomeres reach a critically short length.

Additionally, Epithalon appears to regulate melatonin production from the pineal gland, restoring the circadian rhythm disruptions that accumulate with age. Melatonin itself is a potent antioxidant and immune regulator, so this secondary effect amplifies the anti-ageing profile.

The peptide also modulates gene expression in a broadly youth-associated direction — upregulating antioxidant enzymes and downregulating pro-inflammatory pathways.

What Does The Research Say?

Khavinson's human studies (published 2003-2007) showed Epithalon increased telomere length in elderly patients, improved T-cell immune function, normalised melatonin secretion, and — most notably — reduced all-cause mortality over a 6-year follow-up period. A study of 266 elderly patients showed a 1.6-1.8x reduction in mortality versus controls.

Cell culture studies confirm telomerase activation in human fibroblasts and pulmonary cells. Animal studies show lifespan extension in mice and rats, tumour suppression (counterintuitively, despite telomerase activation), and improved neuroendocrine function.

The caveat: almost all of this research comes from Khavinson's group. Independent Western replication is minimal. The science is plausible and the methodology appears sound, but single-lab findings always warrant caution.

Reported Dosages

Research protocols typically use 5-10mg per day subcutaneously for 10-20 days, repeated every 4-6 months.

Some protocols suggest two cycles per year of 10 days each.

These are research dosages derived from published studies, not medical recommendations.

DISCLAIMER: Epithalon is a research peptide. Not approved for clinical use anywhere outside Russia.

Side Effects & Risks

Published studies report minimal side effects — injection site reactions, occasional mild fatigue. Long-term safety data beyond Khavinson's studies is limited. The theoretical concern with telomerase activation is cancer promotion (telomerase allows unlimited cell division), but Khavinson's studies actually showed tumour suppression, possibly due to improved immune surveillance.

Legal Status by Country